chronic inflammatory demyelinating polyneuropathy

Showing 1 posts of 1 posts found.

robina-weermeijer-ihfopazzjhm-unsplash_5

MHRA approves Takeda’s Hyqvia for chronic inflammatory demyelinating polyneuropathy treatment

March 21, 2024
Medical Communications Hyqvia, MHRA, Neurology, Takeda, chronic inflammatory demyelinating polyneuropathy

Takeda has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation to Hyqvia as a …

The Gateway to Local Adoption Series

Latest content



Pace appoints Ken Beyer as CEO

December 10, 2025